(Press release): Actavis Group, the international generic pharmaceuticals company, today announced plans to expand its manufacturing site in Iceland, increasing capacity at the site by 50%. Fifty new jobs will be created as a result.
The Hafnarfjordur, Iceland manufacturing site exports 95% of its products. After expansion the SOD-site’s capacity will be about 1.5 billion tablets pr. year, depending on the mix of products. Production is expected to start at the new facility by year end 2010, with no disruption to current manufacturing capabilities.
The site produces many of Actavis’ latest generics and specialises in new product launches. Actavis hf in Iceland currently employs about 300 people, mostly in production and quality. By the end of this year, 50 new jobs will be created following the expansion. Actavis Group employs over 10,000 people in 40 countries, including about 570 in Iceland.
The Hafnarfjordur site is ISO 14001 and OHSAS 18001 certified and runs on sustainable energy; electricity from hydropower and geothermal heating. Actavis remains committed to its environmental, health and safety performance, with 11 of its manufacturing sites ISO 14001 certified, seven with an OHSAS 18001 certification.
Actavis is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with 10,000 employees.